

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STACES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO.                                 | F    | ILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO.     | CONFIRMATION NO. |
|---|------|------------|----------------------|-------------------------|------------------|
| 10/797,952                                      |      | 03/11/2004 | Marina Lowen         | SHLI-038-002            | 4856             |
| 37324   | 7590 | 07/20/2006 |                      | EXAMINER                |                  |
| M. ELISA  |      |            | AFREMOVA, VERA       |                         |                  |
| SHIRE LABORATORIES INC.<br>1550 EAST GUDE DRIVE |      |            |                      | ART UNIT                | PAPER NUMBER     |
| ROCKVILL  |      |            | 1651                 |                         |                  |
|   |      |            |                      | DATE MAILED: 07/20/2006 |                  |

Please find below and/or attached an Office communication concerning this application or proceeding.

|  | Application No.   | Applicant(s)    |  |  |  |  |  |
|--|---|-----------------|--|--|--|--|--|
|  | 10/797,952  | LOWEN ET AL.    |  |  |  |  |  |
| Office Action Summary  | Examiner  | Art Unit        |  |  |  |  |  |
|  | Vera Afremova   | 1651            |  |  |  |  |  |
| - The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply   |   |                 |  |  |  |  |  |
| A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). |   |                 |  |  |  |  |  |
| Status   |   |                 |  |  |  |  |  |
| 1) Responsive to communication(s) filed on 11 M 2a) This action is FINAL. 2b) This 3) Since this application is in condition for allowar closed in accordance with the practice under E  | action is non-final.<br>nce except for formal matters, pro  |                 |  |  |  |  |  |
| Disposition of Claims  |   |                 |  |  |  |  |  |
| 4) ☐ Claim(s) 1-21 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-21 are subject to restriction and/or example and the specification is objected to by the Examine 10) ☐ The drawing(s) filed on is/are: a) ☐ access Applicant may not request that any objection to the Replacement drawing sheet(s) including the corrections.  | vn from consideration. election requirement. r. epted or b) objected to by the Edrawing(s) be held in abeyance. See | 37 CFR 1.85(a). |  |  |  |  |  |
| 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.   |   |                 |  |  |  |  |  |
| Priority under 35 U.S.C. § 119   |   |                 |  |  |  |  |  |
| <ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>  |   |                 |  |  |  |  |  |
| Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  Paper No(s)/Mail Date   | 4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa   |                 |  |  |  |  |  |

Application/Control Number: 10/797,952

Art Unit: 1651

## **DETAILED ACTION**

Claims 1-21 are pending and subject to restriction requirement.

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-7and 16-21, drawn to a composition comprising ingredients including serum, non-essential amino acids, transferrin, insulin, epithelial growth factor (EGF), butyrate, hydrocortisone, progesterone and testosterone and to a method of making the composition by admixing the ingredients, classified in class 435, subclass 404, for example.
- II. Claims 8-15, drawn to a method for culturing intestinal cell line in vitro in a medium supplemented with serum, non-essential amino acids, transferrin, insulin, epithelial growth factor (EGF), butyrate, hydrocortisone, progesterone and testosterone, classified in class 435, subclass 375, for example.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case a composition with the presently claimed ingredients can be used for culturing other cells, for example, epidermal cells or keratinocytes. See US 5,712,163 9 (col. 5, lines 20-60).

Application/Control Number: 10/797,952

Art Unit: 1651

Because these inventions are independent or distinct for the reasons given above and have acquired a separate status in the art in view of their different classification, restriction for examination purposes as indicated is proper.

Because these inventions are independent or distinct for the reasons given above and the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

Because these inventions are independent or distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vera Afremova whose telephone number is (571) 272-0914. The examiner can normally be reached from Monday to Friday from 9.30 am to 6.00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached at (571) 272-0926.

The fax phone number for the TC 1600 where this application or proceeding is assigned is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Technology center 1600, telephone number is (571) 272-1600.

Vera Afremova

AU 1651

July 18, 2006

VERA AFREMOVA

V. Hormon

PRIMARY EXAMINER